Characterizing Antibody-Drug Conjugates through Innovative Analytical Solutions
Antibody-Drug Conjugates (ADCs) are a powerful and promising treatment option for patients. This precision-based therapy approach merges antibody specificity with the potency of cytotoxic drugs, enhancing tumor cell targeting while minimizing damage to healthy tissues. ADCs expand treatment options for various cancers and address unmet needs in oncology. An analytical approach to these complex therapeutics that emphasizes detailed characterization and precision can identify and ensure a consistent, high-quality drug product.
Watch our webinar on ADC characterization strategies, where leading experts from Phenomenex and SCIEX will share their knowledge on advancing ADC research and development.
In this session, we will explore case studies related to in-depth ADC characterization:
- Understand how to analyze ADC structural complexities
- Discuss how Biozen Native RP columns from Phenomenex enable LC-MS analysis, under native conditions, to determine DAR (drug-antibody ratio) values, including relevant isomers, for a variety of intact ADCs
- Learn how the Intabio ZT system from SCIEX leverages icIEF-UV/MS and Electron Activated Dissociation (EAD) peptide mapping for multilevel characterization of conjugation end products
speakers
Jose-Carlos, Danaher Corp. Chief Scientific Officer
Jose-Carlos since leaving Pfizer in 2015, Gutiérrez-Ramos has served as a CEO in two emerging biotechs and worked as head of global drug discovery for AbbVie. Although he’s had a front row seat to changes in drug design, he’s also seen how the manufacturing factor of this equation hasn’t fully kept up with the pace of drug development. Today, Gutiérrez-Ramos is leveraging his extensive experience to help overcome some of the lingering manufacturing challenges as the chief science officer of Danaher Corp., a global science and technology conglomerate.
According to Gutiérrez-Ramos, biomanufacturing is the next frontier in innovation for genomic medicines.
gatedform
gatedform
546005641
antibody-drug-wbn
add
Other
promotion
https://lifesciences.danaher.com/
https://help.salesforce.com/s/articleView?id=sf.mc_es_demanager.htm